- Home
- NXRT vs ALLO Comparison
NXRT vs ALLO Comparison
Compare NXRT & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXRT | ALLO |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.4M | 452.6M |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NXRT | ALLO |
|---|---|---|
| Price | $17.70 | $1.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $25.25 | $9.00 |
| AVG Volume (30 Days) | 519.3K | ★ 6.3M |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | ★ 11.54% | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $251,281,000.00 | N/A |
| Revenue This Year | $2.06 | N/A |
| Revenue Next Year | $2.37 | $223.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.67 | $1.04 |
| 52 Week High | $32.36 | $4.46 |
Technical Indicators
Market Signals| Indicator | NXRT | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 35.91 | 37.19 |
| Support Level | N/A | $1.22 |
| Resistance Level | $20.22 | $2.22 |
| Average True Range (ATR) | 0.66 | 0.08 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 8.31 | 43.75 |
Price Performance
Historical ComparisonAbout NXRT NexPoint Residential Trust Inc.
NexPoint Residential Trust Inc is a real estate investment trust company. The trust's objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).